Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Eur J Gastroenterol Hepatol ; 28(7): 777-85, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27097354

ABSTRACT

BACKGROUND: Spontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. METHODS: Two hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. RESULTS: SBP resolved in most of patients in all groups (P>0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. CONCLUSION: Terlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.


Subject(s)
Bacterial Infections/complications , Hepatorenal Syndrome/prevention & control , Liver Circulation/drug effects , Liver Cirrhosis/complications , Peritonitis/complications , Renal Circulation/drug effects , Adult , Bacterial Infections/physiopathology , Drug Therapy, Combination , Female , Hemodynamics/drug effects , Hepatorenal Syndrome/etiology , Humans , Liver Cirrhosis/physiopathology , Lypressin/analogs & derivatives , Lypressin/therapeutic use , Male , Middle Aged , Midodrine/therapeutic use , Peritonitis/physiopathology , Serum Albumin/therapeutic use , Terlipressin , Treatment Outcome , Vasoconstrictor Agents/therapeutic use
2.
APMIS ; 123(12): 1032-9, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26547369

ABSTRACT

To assess the acute effects of partial splenic embolization (PSE) on portal and splanchnic hemodynamics in patients with cirrhosis. Ninety-five patients with hypersplenism were included in the study. Duplex examinations were performed before and 3 and 7 days after PSE. Portal and splanchnic hemodynamics including vessel cross-sectional area (CSA), mean flow velocities (cm/s), blood flows (mL/min), Doppler indices as portal congestion index (CI), liver vascular index, hepatic artery and superior mesenteric artery (SMA) pulsatility and resistive indices (PI and RI), were performed before and after PSE. In our study, 69 of 95 patients were males (72.6%) and 26 females (27.3%). Chronic hepatitis C virus infection was the main cause of cirrhosis (81.1%). PSE failed technically in six patients (6.3%). After PSE, both CSA and CI significantly decreased (p < 0.05 and <0.01). The portal vein velocity significantly increased (p < 0.01). The portal flow volume (892.4 ± 151 mL/min) did not show significant changes. The hepatic artery RI and PI showed a steady increase that became significant 7 days post-PSE (p < 0.05). The RI and PI of SMA increased significantly after 7 days of PSE (p < 0.05). PSE has an immediate portal decompression effect in patients with portal hypertension without reduction in portal flow. This effect on portal pressure should be investigated in future studies as a potential tool for management of acute variceal bleeding when other medical procedures fail.


Subject(s)
Embolization, Therapeutic , Hemodynamics/physiology , Hypersplenism/physiopathology , Liver Cirrhosis/therapy , Liver/blood supply , Splanchnic Circulation/physiology , Adult , Blood Flow Velocity/physiology , Female , Hepatic Artery/physiopathology , Hepatitis C, Chronic/etiology , Humans , Hypersplenism/etiology , Liver/pathology , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Male , Mesenteric Artery, Superior/physiopathology , Middle Aged , Portal System/physiopathology , Portal Vein/physiopathology , Young Adult
4.
Eur J Intern Med ; 22(2): 187-90, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21402251

ABSTRACT

BACKGROUND: Occult HBV infection is defined by detection of HBV DNA in the serum or liver tissue of patients who test negative for HBsAg. The prevalence of occult HBV is higher in hepatitis C virus (HCV) positive patients than HCV negative patients and may have an impact on their clinical outcome. In this study, we evaluated the role of occult hepatitis B virus infection in chronic hepatitis C patients with ALT flare. METHODS: Sixty HBsAg negative patients with chronic hepatitis C virus infection were included. Patients were divided into 2 groups according to their ALT level: 30 patients with normal or slightly high ALT and 30 patients with ALT flare (≥ 5 times normal values). Patients in both groups were examined for the detection of anti-HBs, anti-HBc IgM, and anti-HBc IgG. HBV DNA was detected using semi-nested PCR technique. RESULTS: In patients with normal or slightly high ALT, HBV DNA was detected in 4 (13.3%) patients, while in those with ALT flare, HBV DNA was detected in 19 (63.3%) patients (p<0.001). No association was found between the presence of HBV DNA and various serology markers of HBV infection. CONCLUSION: Presence of occult hepatitis B, with its added deleterious effect, must always be considered in chronic hepatitis C patients especially those with flare in liver enzymes; HBsAg should not be used alone for the diagnosis of HBV infection.


Subject(s)
Alanine Transaminase/blood , Hepatitis B/complications , Hepatitis B/diagnosis , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/enzymology , Liver/enzymology , Adult , Biomarkers/blood , DNA, Viral/blood , Female , Hepatitis B/immunology , Hepatitis B e Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis C, Chronic/virology , Humans , Male , Middle Aged , Serologic Tests , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL